Image description

European Gram Negative AntiBacterial Engine

ENABLE

WELCOME TO ENABLE 



The ENABLE project was launched in February 2014 (ends in January 2020) within IMI's 'New Drugs for Bad Bugs' (ND4BB) programme.

 

The ENABLE consortium is working to advance the development of promising new antibiotic compounds targeting Gram-negative bacteria such as Escherichia coli. The goal of the project is to develop attractive antimicrobial candidates for extensive preclinical studies and  First-in-Human clinical trials, bringing new antibiotics to treat Gram-negative infections one step closer to patients.

 

ENABLE manages a drug discovery and development engine for testing and optimising compounds in all preclinical phases of antibiotic development. ENABLE is an initiative targeted at SMEs and research institutes.


Goals of ENABLE:

    •    three antibacterial Leads
    •    two antibacterial Development Candidates
    •    at least one compound into preclinical and Phase 1 clinical studies

 

 

What can ENABLE do for you?

 

ENABLE is not only a source of funding to advance your most promising compounds, but it is also:


  • an expert knowledge hub at your service

    The Portfolio Management Committee (PMC) of ENABLE is composed of 15 experts from leading EFPIA companies, universities and independent consultants from all over the globe. With their long and extensive expertise in drug discovery, clinical development and anti-bacterials they will mentor your programme and advice on challenges as well as on how to mitigate these.

  • an alliance and collaboration to advance one common goal: fighting AMR

    In ENABLE you will benefit from a well-developed drug discovery and development platform that helps you advance your programme in a very efficient manner. We have experts and staff in many fields including microbiology, chemistry, ADME, in vivo studies and safety that will support you to bring your compound forward.

  • your support for everyday challenges

    The ENABLE team and our experts are easy to approach and eager to support. We can assist you in developing a detailed project plan that is in line with Big Pharma.

  • supporting “raw diamonds”

    If your programme is not yet meeting thresholds with regards to compound maturity or generated data package, ENABLE offers a Material Transfer Agreement (MTA) Route – a kind of pre-ENABLE funding. If accepted, this will also be 100% funded by ENABLE.

  • non-dilutive

     Your compound is your compound and will stay your compound. Programme owners retain full ownership of their asset and all value added through the work of ENABLE. A value sharing agreement has been created within the consortium, where a small percentage of future income generated from the resulting anti-bacterial by the programme owner will be shared between partners. 

  • and of course confidential

    ENABLE has a very restrictive communication policy and only communicates what you agreed upon or released yourself.

 

What ENABLE needs from you for a fruitful cooperation:


  • Commitment, professionalism, transparency, willingness to discuss and - in some cases - adjust plans based on expert advice.

  • Especially for academics: please get in touch with your valorisation offices to clarify the commercialisation potential of the compound.

Interested to join ENABLE?

Please read our "Join us!" section and get in touch: opencall@nd4bb-enable.eu
Image description


LATEST NEWS

 

UPCOMING EVENTS